Mining
Anson Resources (ASX: ASN) is an ASX-listed junior mineral resources company, with a portfolio of minerals projects in key demand-driven commodities.
Its core asset is the Paradox Lithium-Brine Project in Utah, in the USA. Anson is focused on developing the Paradox Project into a significant lithium producing operation. It is currently undertaking a significant resource expansion drilling campaign at Paradox, the results of which will feed into a Detailed Feasibility Study (DFS) at the Project.
The Company’s wider goal is to create long-term shareholder value through the discovery, acquisition and development of natural resources that meet the demand of tomorrow’s new energy and technology markets.
KEY PEOPLE
RELATED STOCKHEAD STORIES
News
In Case You Missed It: A coal takeover attempt and gold plays round out the day
Mining
For lithium-focused Anson, the historical Ajana zinc-lead-silver project is just too good not to drill
News
In Case You Missed It: A bumper brain cancer trial and solid lithium hits
News
In Case You Missed It: O&G production, a graphite plant and a Chilean gold anomaly
News
In Case You Missed It: M&A, asset sales and biotech profits lead the way
Mining
Major Upgrade: Anson announces 45pc jump in Paradox lithium resource
Mining
Notorious DLE: The lithium extraction technologies gunning for the crown
News
In Case You Missed It: Gold sales and big gold hits take the cake
Mining
Well, well, well: Anson unearths two big rare earths targets at Hooley Well
News
In Case You Missed It: Lithium acquisitions and bumper nickel processing for Q3
Mining
Anson advances dual lithium development strategy, selects Green River processing plant site
Mining
Emerging producer Anson plots pathway to maiden resource at Green River with new lithium drilling program
News
In Case You Missed It: A maiden resource and high tech propeller deal
News
In Case You Missed It: It’s wall to wall lithium for the W
Mining
Hooley Dooley: Anson defines 13 new nickel-copper-PGE targets at Hooley Well
News
In Case You Missed It: Visual spodumene and Covid clinical trials
News